Published content in this website is for information purposes and is intended for healthcare professionals only.
Glossary of key terms in PSP
Grasping PSP's intricacies hinges on understanding key definitions and concepts. Familiarity with these principles will help you navigate its complexities.
O-GlcNAcylation
A reversible post-translational modification in which an N-acetylglucosamine (GlcNAc) molecule is added to a protein, regulating its folding, phosphorylation, and degradation. Increased O-GlcNAcylation of tau may counterbalance hyperphosphorylation and promote neuronal survival.
Ocular motor dysfunction
Abnormalities in controlling eye movements, affecting gaze stability and visual tracking.
OGA inhibitor
A molecule that inhibits O-GlcNAcase, increasing protein O-GlcNAcylation and reducing phosporilation, proposed to restore tau homeostasis and reduce neurodegeneration in PSP (i.e. Egalognastat / FNP-223).
Oligodendroglial coiled bodies
Abnormal tau-positive inclusions found within the cytoplasm of oligodendrocytes.
Referências
-
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987
-
Permanne B, Sand A, Ousson S, et al. O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for tau and α-synuclein proteinopathies. ACS Chem Neurosci. 2022;13(8):1296-1314. doi:10.1021/acschemneuro.2c00057
-
Komori T. Pathology of oligodendroglia: an overview. Neuropathology. 2017;37(5):465-474. doi:10.1111/neup.12389